Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Newly diagnosed multiple myeloma patients are often told that their cancer is “incurable but very treatable (?).” It took me years to figure out what this meant. I am a long-term survivor of multiple myeloma. The challenge all myeloma patients face is that conventional oncology considers myeloma to be incurable. Therefore, MMers must either accept the inevitable or look for ways to improve on the long and growing list of conventional (FDA approved) therapies. Wobenzym N, according to the study linked and excerpted below, is one such integrative cancer therapy.
“Wobenzym N – is a broad spectrum blend of enzymes that has shown the ability to fight cancer, reduce blood clots, heal radiation damage and increase the efficacy of chemotherapy. I take the directed dose daily before meals.
“The enteric-coated enzyme preparation (Wobenzym N – ) contained 100 mg of papain, 40 mg of trypsin, and 40 mg of chymotrypsin per tablet…The proportion of patients achieving complete remission, partial remission, or stable disease was significantly higher in the enzyme group than in the control group.”
If you or a loved one have been diagnosed with Multiple Myeloma, let me say this loud and clear:
It is critical that you become an active participant in your care. Learn everything you can.
Your decision-making begins by learning about the full spectrum of evidence-based myeloma therapies, both conventional and non-conventional. Here are some questions you may have right now:
Living with, researching and coaching multiple myeloma since early ’94 has taught me that conventional oncology, though an important piece of the MM picture, is only one piece. MM patients and survivors must think outside the box.
Out-of-the-box thinking, in the case of the article linked below, is the idea of MM “prehabilitation” with wobenzym as well as moderate exercise, anti-angiogenic nutrition, and anti-MM supplementation such as curcumin, green tea extract, omega-3 fatty acids, resveratrol and others.
To learn more about evidence-based conventional and non-conventional MM therapies, such as wobenzym N, scroll down the page, post a question or comment and I will reply to you ASAP.
“Results: Significantly higher overall response rates and longer duration of remissions were observed in the OE-group. Primary responders showed a longer mean survival time than non-responders. Additive therapy with OE given for more than 6 months decreased the hazard of death for patients at all stages of disease by approximately 60%. Observation time was not long enough to estimate the median survival for patients at stages I and II; for stage III patients it was 47 months in the control group versus 83 months for the patients treated with OE (P = 0.0014) which means a 3-year gain of survival time. Significant prognostic factors for survival, in the Cox regression analysis, were stage of disease and therapy with OE. The OE-therapy was generally well tolerated (3.6% of patients with mild to moderate gastrointestinal symptoms).
CONCLUSION: OEs represent a promising new additive therapy in multiple myeloma which will be further evaluated in a randomized phase III trial in the USA.”
“The authors present information on the presence of adhesive proteins on membranes of myeloma and precursor cells isolated from bone marrow and blood from a group of 33 patients examined by fluorescent flow cytometry.
They also compare the density of integrins (CD29, CD49e, CD41, CD51 and CD61) and adhesive proteins from the group of “homing” receptors (CD44) and IgG “superfamily” (LFA-1, LFA-3, ICAM-1, N-CAM) and their changes after a single oral dose of a mixture of proteolytic enzymes (Wobe Mugos, Wobenzym, MUCOS Pharma, FRG).
The authors observed a significant drop of CD29, CD54 (ICAM-1), CD58 (LFA-3) after Wobe Mugos, CD49, CD51, CD58 after Wobenzyme.
The insignificant decline of density of CD44 on cells, as well as of the soluble receptor of CD44 after oral administration of proteolytic enzymes in serum, incl. the mentioned changes of integrins and other adhesive proteins, indicate the importance of enzyme preparations in the supporting treatment of malignant processes.”
Remember that clinical trials rarely, if ever, include patients over the age of 70. This means that most if not all FDA research does not apply to the MM patient over the age of 70.
Older MMers don’t know how lucky they are. My reasoning is common sense:
Lastly, the regimen recommended by your oncologist is not curative. Research on curcumin, omega-3, vitamin D3, and green tea extract, etc. allows for the possibility of living a better, longer life as an mmer. I have remained in complete remission from my own multiple myeloma by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, antioxidantation, life style, bone health and mind-body therapies.
“Data thus far suggest that continuously administering lenalidomide and dexamethasone in older patients until the disease returns is superior to MPT as initial treatment…The 4-year OS rate was 47% in both lenalidomide arms versus 39% with MPT…
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“Significantly higher overall response rates and longer duration of remissions were observed in the OE-group. Primary responders showed a longer mean survival time than non-responders. Additive therapy with OE given for more than 6 months decreased the hazard of death for patients at all stages of disease by approximately 60%…”
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”